A Study to Determine the Bioavailability of Various Formulations of GDC-0134 in Healthy Female Participants of Non-Childbearing Potential

Inclusion Criteria

- Body mass index (BMI) range 18.5 to 35 kilograms per square meter (kg/m2)

- In good health, determined by no clinically significant findings from medical history,
physical examination, 12-lead ECG, and vital signs;

- Clinical laboratory evaluations within the reference range for the test laboratory,
unless deemed not clinically significant by the principal investigators (PIs)

- Females of non-childbearing potential only

Exclusion Criteria

- History or clinical manifestation of any significant medical condition as determined
by the PI (or designee)

- History of significant hypersensitivity, intolerance, or allergy to any drug compound,
food, or other substance, unless approved by the PI (or designee)

- History of stomach or intestinal surgery or resection that would potentially alter
absorption and/or excretion of orally administered drugs

- Use of any prescription medications/products within 14 days prior to Check-in (Day -1)
for their first treatment period and during the entire study duration, unless deemed
acceptable by the PI

- Use of oral antibiotics within 4 weeks or intravenous antibiotics within 8 weeks prior
to the Screening evaluation and during the entire study duration

- Use of any over-the-counter, non-prescription preparations within 14 days prior to
Check-in (Day -1) for their first treatment period and during the entire study
duration, unless deemed acceptable by the PI

- Use of acid reducing medications (proton pump inhibitors [PPIs], histamine H2-receptor
antagonists [H2RAs]) within 14 days prior to Check-in (Day -1) for their first
treatment period and during the entire study duration. As an alternative, antacids may
be allowed at least 4 hours before or after dose

- Use of any vaccines (including seasonal flu and H1N1 vaccines) within 14 days prior to
Check-in (Day -1) for their first treatment period

- Use of tobacco- or nicotine-containing products within 6 months prior to Check-in (Day
-1) for their first treatment period and during the entire study

- Any acute or chronic condition or any other reason that, in the opinion of the PI,
would limit the subject's ability to complete and/or participate in this clinical
study